3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
186
pembrolizumab
151
Magnetic Resonance Spectroscopy
151
Carboplatin
114
Biopsy
104
Cyclophosphamide
96
Cisplatin
88
Paclitaxel
79
Gemcitabine
71
Bevacizumab
68
fludarabine
60
Nivolumab
58
Fluorouracil
51
Radiotherapy
49
Dexamethasone
47
Capecitabine
47
Pemetrexed
46
Oxaliplatin
44
Docetaxel
44
Rituximab
43
Leucovorin
41
Doxorubicin
40
venetoclax
39
durvalumab
39
atezolizumab
39
Temozolomide
32
Standard of Care
32
Radiation
32
Cetuximab
32
130-nm albumin-bound paclitaxel
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled